🇩🇪 DE Neues Betriebsmodell-Projekt
🇬🇧 FR Projet de nouveau modèle opérationnel
🇪🇸 ES Proyecto de nuevo modelo operativo
🇨🇳 ZH 新运营模式项目
🇰🇷 KO 새 운영 모녂 프로잨트
🇦🇪 AR مشروع نموذج التشغيل الجديد
🇮🇹 IT Nuovo progetto di modello operativo
🇧🇷 PT-BR Projeto de novo modelo operacional
A New Operating Model for Rare Disease
Not a reimagination of the existing process. A new one, built from the patient backward, eliminating every step that does not serve speed, safety, or efficacy. The data has to travel with the patient — not the health system, not the insurer, not the institution. The patient.
There is a category of disease where the development timeline is not just a failure of science. It is a failure of architecture. The operating model of drug development was not designed for a disease affecting 500 people globally. It was designed for blockbusters, for populations of hundreds of thousands, for review processes built around the assumption of time.
Rare disease patients do not have time. The five diseases in this framework have mortality windows of two to five years from diagnosis. The current model averages twelve to fifteen years from discovery to patient access. That gap is structural, not scientific. And it is a gap that kills.
The model in this work is not a reimagined process. It is a new one. Built from the patient backward. Every step exists only if it serves speed, safety, or efficacy. If it serves review, administration, or institutional protection, it gets compressed or removed. The patient is the record. The data travels. The clock starts at first symptom, not at first IND filing.
The economic model is not charity. A $966B annual burden on the US economy alone. A $262B global orphan drug market projected to exceed $500B by 2030. A development timeline where every year compressed represents life-years returned, cost-of-illness reduced, and earlier revenue entry for effective therapies. The case for this model is financial, clinical, and institutional simultaneously.
Quantum is included in this framework not as aspiration but as architecture. The Patient “Living” Record is only as trustworthy as its measurements. Quantum sensing does not drift. The cold chain verification required for a gene therapy at $2.1M per patient with no second dose requires a record that is physics-confirmed, not carrier-reported. The operating model does not wait for quantum. It runs without it. But it is designed so that when quantum reaches maturity at each contact point, it slots in as a verified upgrade to a system already running. Not a dependency. A planned acceleration.
Use the section navigation above to move through the full work: the five diseases, the bloat cited by phase, the new operating model, the system map, the economic case, the quantum hypothesis, and the sources.
Going to a quantum clinic should feel like going to your corner drugstore or your dry cleaner. Routine. Accessible. Something you do because it works. That is the bar. This framework is in active development. If you are working on rare disease drug development, patient registries, cold chain infrastructure, or quantum sensing applications in healthcare, the conversation is open.
Five diseases. Five clocks no one should be forced to wait on.
Selected by mortality burden, pace of disease, diagnosis delay, and therapeutic inadequacy. Pulmonary fibrosis is included because it must be.
A crystallizing, irreversible fibrotic cascade. Only two approved treatments slow, not stop, decline. Lung transplant is the only curative option, viable for fewer than 5% of patients. The disease progresses while the system reviews.
Total motor neuron death. No curative therapy. Three approved drugs extend life by months. The clinical trial failure rate exceeds 95%. By the time most patients enroll in a trial, their disease has progressed beyond the study’s target population. The function-first system misses them entirely.
A child diagnosed today will likely spend their teenage years in a wheelchair and their twenties on ventilatory support. Gene therapy is in trial. Exon-skipping drugs are approved for subsets. Manufacturing complexity for personalized therapies creates supply fragility at exactly the moment patient populations are small and irreplaceable. The handoffs between research, manufacturing, and clinical care are where these patients fall.
SMA is the rare disease success story. Zolgensma and nusinersen have changed outcomes dramatically. But access, cold chain integrity, and the gap between approval and administration remain failure points. The therapy exists. The delivery system is what fails patients. That gap is a data continuity problem, not a science problem.
CF is the model for what is possible when science, community, and manufacturing align. CFTR modulators have transformed it from a progressive fatal disease into a manageable chronic condition. The lesson is not about the drug. It is about what happened when the data traveled with the patient across every function, every system, every border. The other four diseases need that same continuity. CF proves it is possible.
Where the time goes. What it costs in lives.
Average rare disease drug development: 12–15 years from discovery to patient. Diagnosis delay: five years or more for most rare disease patients (2026). Of more than 10,000 identified rare conditions globally, fewer than 500 have an approved treatment. The time is not all necessary. Much of it is structural. And most of the structure exists to serve functions, not patients.
Not a reimagined process. A new one.
Everyone wants to own a function. What they forget are the handoffs. The data has to travel through systems, processes, functions, and borders. With the patient. Not with the institution that treated them last. Not with the insurer that paid the last claim. With the patient.
Five principles: (1) The patient is the record — a living data model, not a submission package. (2) Parallel, not sequential — every workstream runs simultaneously. (3) The clock starts at first symptom, not at first IND. (4) The record never closes — approval is a checkpoint, not an endpoint. (5) Every step is measurable: time, cost, outcome, and life-years saved.
The five pillars of the new model
The patient is the anchor. From first symptom — not first diagnosis, not first enrollment — a continuous, physics-informed (sensors, cold chain, environmental condition), longitudinal data record follows the patient. Genomic, phenotypic, environmental, treatment response. Not compiled for a dossier. Never closed. Available to every authorized participant: the treating physician, the trial, the regulator, the payer. The record travels. The physician does not rebuild it from memory at every transition of care. The insurer does not dispute what the previous institution documented. The record is the thread.
Pre-clinical, natural history, manufacturing process development, and regulatory engagement run in parallel, not in sequence. The IND is a checkpoint, not a gate. The NDA is a summary of continuous submission, not a document compiled on a deadline. No step waits for another step to close before beginning. The critical path collapses because there is no single critical path. There are parallel ones, all sharing the same underlying patient record.
A disease-specific platform trial — not a sponsor-specific one — evaluates multiple interventions against shared controls. The control arm is the living patient record. Interim analyses run continuously. Futile arms stop. Promising arms accelerate. Validated biomarkers replace mortality endpoints where a mortality-endpoint trial is ethically indefensible for a disease with a 3-year window. No patient waits 7 years for a result in a disease where 3 years is the median survival.
Commercial-scale manufacturing authorization begins at successful Phase II. Inventory is built in parallel with Phase III under a conditional manufacturing authorization. At approval, patients receive therapy within days, not 18 to 36 months later. For cell and gene therapies: redundant manufacturing nodes, not single-site dependency. The supply chain is validated before approval, not assembled after it. The handoff from manufacturing to distribution to administration is documented in the same record that began at the patient’s first symptom.
The condition of a therapy from manufacturing site to point of administration must be independently verified, not carrier-reported. For a gene therapy at $2.1M per patient with no second dose, the administration record must be defensible to every relying party: the payer, the regulator, the patient’s family. A cold chain record that was broken and undetected is not a cold chain record. It is a liability. That record is part of the patient’s continuous data thread. It does not live at the carrier. It travels with the dose.
The new operating model, visualized
New nodes (the living record, parallel orchestration, platform trials) replace the sequential bottlenecks of the old model. Hover any node for context.
Measurable for everyone at the table.
The new operating model is not a research proposal. It has an economic model, a productivity model, and a revenue model. These are the numbers that anchor it.
The three models
Financial architecture: five diseases
The revenue model only holds if you model it accurately. For IPF, ALS, DMD, SMA, and CF, the financial mechanics below are structural realities that determine whether a therapy can be commercialized, priced, and sustained. They are not optional line items. Each dimension is disease-specific.
1. Gross-to-net waterfall: WAC is not collected revenue
Nintedanib and pirfenidone are both Medicare Part D drugs. IRA inflation rebate penalties apply if WAC increases exceed CPI-U. The 2024 Part D redesign shifts catastrophic-phase liability to manufacturers (20%). PBM rebates and Medicaid Best Price set the floor. Net-to-gross discounts on established ILD therapies run 30–50% of WAC. A new entrant pricing above $80K/yr faces formulary exclusion without deep rebate concessions.
ALS faces the smallest US patient population (≈30K) and highest per-patient cost pressure. 340B hospital pricing applies at ALS specialty centers. Medicare is the dominant payer (median onset age 55–65). First-year direct care exceeds $47K before drug costs. IV-administered ALS therapies face additional hospital GTN mechanics via DRG assignment. Net revenue realization on a $150K–$200K WAC ALS drug is typically 55–65% after full GTN.
DMD is pediatric-onset — Medicaid is the dominant payer through childhood and adolescence. Medicaid Best Price is the binding floor. Exon-skipping drugs carry orphan designation: 7-year exclusivity plus a potential 6-month pediatric extension. 340B pricing at children’s hospitals further compresses net. For gene therapy entrants at $3M+ list, outcomes-based contracts with milestone repayment are becoming a payer prerequisite — model installment revenue recognition, not lump-sum at administration.
Zolgensma ($2.1M list) is the reference case for gene therapy GTN mechanics. Medicaid is the dominant payer for infants. CMS implemented outcomes-based contracts with installment payment structures. BPCIA biologics exclusivity (12 yr) and orphan drug exclusivity (7 yr) overlap — model the more protective, not both stacked. Nusinersen at $750K year-1 / $375K thereafter demonstrates how payer-mix shift from commercial to Medicaid compresses blended net realization over cohort life.
Trikafta/Kaftrio is the most commercially mature rare disease asset (WAC ≈$311K/yr). Net realization after PBM rebates, Medicaid Best Price, 340B, and Part D redesign is estimated at 55–65% of WAC. IRA small-molecule negotiation applies at 9 years post-approval (Trikafta approved 2019; MFP eligibility: 2028). CF is the model case for how GTN mechanics compound over product lifecycle as Medicare share grows with patient longevity improvement and as IRA MFP kicks in.
2. Tax credits, grants & non-dilutive capital
3. Regulatory exclusivity, IRA triggers & LOE erosion curves
Model architecture checklist: by disease
Quantum as mechanism
Something is happening in physics labs, cold chain logistics nodes, and genomics research centers that most pharmaceutical organizations have not yet registered. It is not hype. It is not science fiction. It is early-stage, uneven, and in some places closer than the headlines suggest. The question is not whether quantum belongs in this model. The question is whether we have the architecture ready when it arrives.
Every generation of technology that was going to transform drug development turned out to be only as good as the process it ran on. Genomics. AI. Real-world evidence platforms. Each one arrived with genuine promise, got layered onto a broken operating model, and produced a faster version of the same failure. The handoffs stayed broken. The data still did not travel with the patient. We got better tools inside a structure that was never designed to use them.
Quantum is next in that line. And the risk of repeating the same mistake is real.
Drug development today carries a clinical failure rate above 90% and an average cost above $2.6B per approved medicine, with timelines exceeding ten years from discovery to market. Frontiers in Drug Discovery, 2026 That failure rate is structural. It is not a hardware problem. No quantum processor, however powerful, fixes broken handoffs. No sensing technology, however precise, creates a record that was never designed to travel.
The operating model in this framework is the prerequisite. Build the architecture first. Define what the data must do. Where it must travel. What continuity means across systems, functions, and borders. Get that right, and quantum becomes an accelerant. Skip it, and quantum becomes the next expensive layer on a process still producing the same outcomes.
The first is verification. The Patient “Living” Record is only as trustworthy as its measurements. Classical sensors drift. They are tampered with. They produce records that are operator-reported, not physics-confirmed. That distinction matters enormously when a gene therapy costs $2.1 million per patient with no second dose and no reversal.
Quantum sensing does not drift in the same way. The measurement is the proof. As of January 2025, the NIHR had identified 63 quantum sensing technologies with active healthcare applications, 78% still at early readiness (TRL 1 to 5) but six already at TRL 9. NIHR, Quantum Sensing in Healthcare, Jan 2025 The physics to verify condition at every node of the cold chain already exists in deployable form. The architecture to use it is what has been missing.
The second is pattern recognition in sparse data. Rare disease genomic and phenotypic datasets are high-dimensional and very small. Classical machine learning was not built for this. Coupled-cluster computation hits a hard wall at roughly 20 to 30 atoms, unable to model the electron correlation that drives binding selectivity in rare disease targets. Frontiers in Drug Discovery, 2026 Quantum-enhanced methods operate differently on that kind of data. Earlier biomarker identification. Earlier patient identification. Earlier signal from the platform trial, in populations too small for classical models to work confidently.
Neither capability is production-ready today. Both are on a development curve that intersects with this model’s deployment horizon. That is the bet worth making.
“The operating model does not wait for quantum. It runs without it. But it is designed so that when quantum reaches maturity at each contact point, it slots in as a verified upgrade to a system already running. Not a dependency. A planned acceleration.”
2. The Platform Trial. This is where I find the most hope. Rare disease populations are small. Sometimes 200 patients globally. Sometimes fewer. Classical models fail here, not because they are poorly designed, but because they were never built for data this sparse and this high-dimensional. Research published in 2025 and 2026 identifies rare disease genomics as one of the highest-potential near-term applications of quantum machine learning. npj Digital Medicine, 2026 Earlier biomarker signals. Earlier interim analysis. Earlier adaptive decisions in an arm that might represent fewer than 50 patients in the world.
3. Cold Chain Verification. Gene therapies do not tolerate temperature excursions. A single break in cold chain can destroy a dose that took years and millions to produce, and cannot be replaced for a patient whose window may have passed. Quantum random number generation using Hadamard and Toffoli gate circuits creates tamper-evident records that are cryptographically unbreachable by classical or quantum adversaries. Peer-to-Peer Networking and Applications, Springer, 2025 Combined with distributed ledger and IoT sensor networks, the cold chain record becomes physics-confirmed at every node.
4. Regulatory Data Provenance. A rolling, living submission to a regulator requires that every data point be traceable, verifiable, and timestamped in a way that cannot be retroactively altered. That is not a feature request. That is the condition of trust. Quantum-secured provenance closes that gap without adding process overhead, and regulatory submissions are specifically identified as a near-term application by the pharma quantum research community. Drug Discovery World, April 2025
Quantum computing for drug discovery is early. TRL 2 to 3 as of 2026. No NISQ-era workflow has solved a pharmaceutically relevant problem in a deployed industrial setting. The published demonstrations all use small-molecule toy systems, carefully chosen to show what is possible, not yet what is production-ready. Fault-tolerant systems capable of full rare disease genomic simulation are post-2030, most estimates suggest. Frontiers in Drug Discovery, 2026 That is not a dismissal. That is a timeline. And it is a timeline that intersects with where this operating model will be in four to six years if the work starts now.
Quantum sensing is a different story. Six of the 63 identified healthcare quantum sensing technologies were already at TRL 9 as of 2025. Regulatory pathways are forming: Chipiron’s low-field quantum MRI system is targeting FDA 510(k) clearance in April 2027. The UK National Quantum Strategy Mission 3 target is NHS-wide quantum sensing deployment by 2030. NIHR, 2025 Cold chain quantum sensing is not a future possibility. For some applications, it is an engineering integration problem.
Regulatory validation frameworks for quantum-verified data are estimated to lag hardware readiness by three to five years. QuanMed AI, 2026 That gap is real. And the way to close it is to have an operating model already running that generates evidence regulators can evaluate. You cannot negotiate a framework in the abstract. You need data from a real system.
AstraZeneca has publicly targeted quantum-accurate virtual screening by 2030. Google’s quantum chemistry roadmap targets simulation of 100+ active electrons by the same year. QuanMed AI, 2026 These are not aspirational statements from organizations known for aspirational statements. They are engineering commitments from organizations that have already made significant investments. The timeline is real. It is not today. But it is close enough that the architecture question has to be answered now.
The question worth sitting with: If a child is diagnosed today with a condition affecting fewer than 500 patients globally, and quantum sensing can verify every measurement in her record, and quantum computing can find the biomarker signal in a trial too small for classical models to read, what does the development timeline look like? Not as a prediction. As a design challenge. The operating model defines the architecture. Quantum defines what that architecture can eventually run at. The work of this framework is to make sure the structure is ready.
Cited references
All statistics and claims in this framework are drawn from publicly available, peer-reviewed or institutional sources, updated through 2026 where available. No company, sponsor, CMO, CDMO, or CRO is cited or referenced.
Quantum
- NIHR (Jan 2025). Emerging applications of quantum sensing technology in healthcare. 63 technologies identified, TRL distribution, UK National Quantum Strategy Mission 3.
- Frontiers in Drug Discovery (2026). Quantum-machine-assisted drug discovery. TRL 2–3 current state, classical scaling limits, fault-tolerant systems post-2030.
- npj Digital Medicine (2026). Advancing genomics and integration of multi-omics for precision oncology using quantum machine learning.
- Nature Reviews Physics (2025). How quantum biosensing is transforming healthcare. NV diamond sensors, Q-BiC biocompatible chip, clinical translation pathways.
- Peer-to-Peer Networking and Applications, Springer (2025). Sustaining immutability in pharmaceutical cold supply chain integrating quantum blockchain.
- Drug Discovery World (April 2025). How quantum computing is revolutionising drug development.
- QuanMed AI (2026). Quantum computing in healthcare: timeline, applications and reality check.
- Cell Patterns (2025). How quantum computing can enhance biomarker discovery.
- National High School Journal of Science (2025). Advancing drug discovery with quantum computing: breaking artificial intelligence barriers.
Disease Burden & Epidemiology
- Global burden of interstitial lung diseases and pulmonary sarcoidosis 2000–2021 (PMC / NCBi, 2024)
- Cystic Fibrosis Mortality Trends 1999–2024 (CDC WONDER Study, PMC, 2024)
- ALS Facts and Statistics (ALS News Today)
- ALS care costs over $47,000 in the first year (ALS Association / Newswise)
- Hope for rare diseases (The Lancet, 2024)
Drug Development Timeline & Process
- Drug Development Timeline: Why It Takes Over 10 Years (intuitionlabs.ai)
- Accelerating Rare Disease Drug Development: A Strategic Framework (ERGOMED, 2024)
- Challenges in Rare Disease Drug Development: A Statistical Perspective (arXiv, 2024)
- FDA Coordination of Rare Disease Drug Development (GAO Report, 2025)
- Regulatory Pathway for Cell and Gene Therapies (HMPI, 2024)
Diagnosis Delay
Economics
- Economic Burden of Rare Diseases (Health Affairs, 2022)
- Optimizing Pricing and Access for Rare Disease Drugs (Oliver Wyman, 2024)
- Rare Disease Treatments: Navigating the Economics of Global Innovation (PharmTech, 2026)
- Rare Disease Day 2026: A New Economic Reality
- Economic Burden of Rare Diseases 10x Higher Than Mass Market (AJMC)